Toggle light / dark theme

Analysis of circulating tumour DNA (ctDNA) is commonly used for molecular profiling in patients with advanced-stage non-small-cell lung cancer (NSCLC). The authors of this Review summarize the available evidence on the potential utility of incorporating ctDNA in the management of those with early stage and locally advanced NSCLC and propose interventional studies to provide the necessary additional evidence.

Leave a Comment

If you are already a member, you can use this form to update your payment info.

Lifeboat Foundation respects your privacy! Your email address will not be published.